Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.92 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766127 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL1063806 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL964558 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL16649235 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrahexylammonium SCHEMBL2521928 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL13567361 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL4059060 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL1060273 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL158607 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL4059099 | 0.96 | SLC22A1 (0.93) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0159624-B1 | MOLECULAR SIEVE COMPOSITIONS | UOP (US) | 1991-12-18 | — | — | EP | claimed |
| US-20230234934-A1 | BIOACTIVE PHENOLATE IONIC COMPLEXES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234934-A1 | BIOACTIVE PHENOLATE IONIC COMPLEXES | PHOSPHO1, ACP3, BET1 | SLC22A1 4242/4885SLC22A2 4389/4885ALDH1A1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.